News & Trends2026-04-20Carelogy編集部
AIM Kidney Drug for Cats: 2026 Approval Update — How It Works, Efficacy & Expected Cost
The AIM protein drug for feline chronic kidney disease has been submitted for approval in Japan (April 2026). We break down clinical trial data, mechanism, expected cost, and what owners should do now.
What Is the AIM Drug? A Groundbreaking Approach to the Root Cause of Feline CKD
Feline chronic kidney disease (CKD) affects approximately 81% of cats over 15 years old and is the leading cause of death in cats. Until now, treatments could only slow progression — no cure existed.
The AIM drug may fundamentally change this.
How AIM protein works:
AIM (Apoptosis Inhibitor of Macrophage) is a protein naturally present in the blood of all mammals. In healthy animals, AIM acts as a "cleanup crew," removing dead cell debris (waste) that accumulates in kidney tubules.
However, cats have a structural defect in their AIM:
- In humans and dogs, AIM floats freely in blood and reaches the kidneys when needed
- Cat AIM remains tightly bound to IgM antibodies and cannot detach
- This means AIM never reaches the kidneys → waste accumulates → inflammation → kidney failure
This is why cats develop kidney disease at abnormally high rates compared to other mammals. The AIM drug provides functional AIM protein from outside, compensating for this feline-specific weakness.
The discovery was made by Professor Toru Miyazaki of the University of Tokyo, who raised approximately ¥14 million through crowdfunding in 2021 to accelerate research.
Clinical Trial Data: Disease Progression Halted in Stage 3 Cats
Clinical trials for the AIM drug were conducted jointly by the AIM Institute of Medical Science and IAM CAT Co., Ltd.
Trial overview:
- Subjects: Cats with CKD Stage 3 (creatinine 2.9-5.0 mg/dL per IRIS criteria)
- Administration: Injection (exact dosing intervals not yet publicly disclosed)
- Follow-up: Months to years of monitoring
Confirmed effects:
- Disease progression halted: In cats that began treatment at Stage 3, further deterioration of kidney function was suppressed
- Improved general condition: Recovery of appetite, increased activity levels, and improved coat quality were reported
- Long-term survival: Cases of cats surviving 5+ years after starting AIM treatment have been documented
Critical caveats — this is NOT a "miracle cure":
- It does not regenerate damaged kidney tissue
- Effectiveness is limited in Stage 4 (end-stage) disease
- The effect is "halting progression," not "reversing damage"
- Early detection and early treatment maximize benefit
Expected benefit by CKD stage:
| CKD Stage | Creatinine | Expected Benefit |
|---|---|---|
| Stage 1 | <1.6 mg/dL | Excellent — preventive use possible |
| Stage 2 | 1.6-2.8 mg/dL | Excellent — significant slowing expected |
| Stage 3 | 2.9-5.0 mg/dL | Good — efficacy confirmed in trials |
| Stage 4 | >5.0 mg/dL | Limited — less effective at end-stage |
midArticleCta.byCategory.news.title
midArticleCta.byCategory.news.description
Used by 230,000+ cat owners in 50 countries
Approval Timeline and Expected Cost
Current status (as of April 2026):
1. ✅ Clinical trials completed
2. ✅ Stability testing completed (March 2026)
3. 📋 Submission to Japan's Ministry of Agriculture (April 2026)
4. ⏳ Review period (typically 6-12 months)
5. 🎯 Target availability: Late 2026 to early 2027
Expected cost:
Official pricing will be announced after approval, but estimates can be made based on comparable veterinary drugs:
- New veterinary drugs typically cost ¥3,000-10,000 per dose
- If ongoing treatment is needed, monthly costs of ¥5,000-15,000 are expected
- Pet insurance coverage is possible but will vary by provider
Cost-effectiveness perspective:
Conventional CKD management (prescription diet + regular testing + fluid therapy) costs ¥10,000-30,000/month. If AIM can halt progression, it may reduce long-term treatment costs.
What owners can do now to prepare:
1. Get regular blood work done (annually; twice yearly for cats 7+) → Health check guide
2. Track BUN, creatinine, and SDMA values over time
3. Consider pet insurance enrollment (in case the new drug becomes covered)
4. Discuss the AIM drug with your regular veterinarian
How AIM Fits with Existing CKD Management
Even after AIM becomes available, conventional CKD management will not become obsolete. In fact, AIM combined with existing therapies is expected to be the most effective approach.
Conventional therapies remain essential:
| Treatment | Purpose | Relationship with AIM |
|---|---|---|
| Kidney prescription diet | Reduce kidney burden via phosphorus/protein restriction | Use together |
| Subcutaneous fluids | Prevent dehydration, promote waste elimination | Combine as needed |
| Phosphorus binders | Control blood phosphorus levels | Use together |
| Antihypertensives | Prevent hypertension-related kidney damage | Use together |
| Hydration strategies | Reduce kidney workload | Always important |
What AIM changes is the "progression curve":
- Previously: Stage 2 → 3 → 4 → end-stage, irreversibly
- With AIM: Progression halted (or dramatically slowed) at a given stage
- Result: The period manageable with diet + fluids could be greatly extended
"Cats living to 30" — reality check:
Some media have reported that AIM could extend cat lifespan to 30 years, but this is overly optimistic. However, if CKD progression can be halted, more cats will live until they reach end-of-life from causes other than kidney failure. A realistic estimate is that average lifespan could increase by 3-5 years — which is still revolutionary.
CatsMe Supports Early Detection of Kidney Disease
To maximize the benefit of the AIM drug, early detection is paramount. Catching CKD at Stage 1-2 means the greatest potential benefit.
What CatsMe can do:
- Water intake & urination tracking — Quantify "increased thirst and urination," the earliest CKD symptom
- Weight change monitoring — Gradual weight loss is an early CKD indicator
- AI health analysis — Detect behavioral pattern changes that signal emerging issues
- Blood test result logging — Track BUN, creatinine, and SDMA values over time
- Vet-ready reports — Share months of data in a clear, visual format
Whether your cat is "still at Stage 1" when AIM becomes available depends on the health records you start keeping today.
Start tracking your cat's health with CatsMe →
Could you answer "when did this start?"
When your vet asks, don't be left guessing. CatsMe automatically logs daily health scores you can share with one tap.
AIM腎臓病新薬CKD宮崎徹2026
FAQ
Be ready the moment you sense something's off
You're reading this because you care deeply about your cat's health. With CatsMe, you can run an AI health check the instant worry strikes.
Related Articles
News & Trends